2014年的合成代谢骨疗法：用于骨质疏松症的新型骨形成治疗方法。 - Suppr

Suppr

超能文献

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.

作者信息

Papapoulos Socrates E

机构信息

Center for Bone Quality, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.

出版信息

Nat Rev Endocrinol. 2015 Feb;11(2):69-70. doi: 10.1038/nrendo.2014.214. Epub 2014 Dec 9.

DOI:10.1038/nrendo.2014.214

PMID:25488486

Abstract

摘要

相似文献

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.2014年的合成代谢骨疗法：用于骨质疏松症的新型骨形成治疗方法。

Nat Rev Endocrinol. 2015 Feb;11(2):69-70. doi: 10.1038/nrendo.2014.214. Epub 2014 Dec 9.

[Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].[骨合成代谢药物与即将上市的骨质疏松症治疗药物]

Reumatizam. 2014;61(2):95-9.

Mechanisms of anabolic therapies for osteoporosis.骨质疏松症的合成代谢治疗机制。

N Engl J Med. 2007 Aug 30;357(9):905-16. doi: 10.1056/NEJMra067395.

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.内分泌疾病的管理：骨质疏松症的新型合成代谢治疗方法

Eur J Endocrinol. 2018 Feb;178(2):R33-R44. doi: 10.1530/EJE-17-0920. Epub 2017 Nov 7.

[Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].[骨质疏松症的治疗创新（抗硬化蛋白抗体和地诺单抗）]

Ann Endocrinol (Paris). 2011 Oct;72 Suppl 1:S15-22. doi: 10.1016/S0003-4266(11)70005-1.

[Update and perspectives of anabolic therapies for osteoporosis].[骨质疏松症合成代谢疗法的更新与展望]

Clin Calcium. 2012 Mar;22(3):327-33.

Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.靶向抑制骨硬化蛋白治疗绝经后骨质疏松症：作用机制的批判性评估。

Eur J Pharmacol. 2018 May 5;826:39-47. doi: 10.1016/j.ejphar.2018.02.028. Epub 2018 Feb 22.

Two pioneering osteoporosis drugs finally approach approval.两种开创性的骨质疏松症药物终于接近获批。

Nat Rev Drug Discov. 2016 Jun 30;15(7):445-6. doi: 10.1038/nrd.2016.132.

Anabolic Therapy for the Treatment of Osteoporosis in Childhood.儿童骨质疏松症的合成代谢治疗。

Curr Osteoporos Rep. 2018 Jun;16(3):269-276. doi: 10.1007/s11914-018-0434-z.

Anabolic therapy in glucocorticoid-induced osteoporosis.糖皮质激素诱导性骨质疏松症的合成代谢疗法。

N Engl J Med. 2007 Nov 15;357(20):2084-6. doi: 10.1056/NEJMe0706770.

引用本文的文献

Comparison of unipedicular and bipedicular kyphoplasty for treating acute osteoporotic vertebral compression fractures in the lower lumbar spine: a retrospective study.单双侧入路椎体后凸成形术治疗下腰椎骨质疏松性椎体压缩骨折的比较：一项回顾性研究。

BMC Musculoskelet Disord. 2023 May 23;24(1):410. doi: 10.1186/s12891-023-06545-0.

A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment.特立帕肽治疗与长期双膦酸盐治疗相关的非典型股骨骨折的简要综述及临床证据

Front Surg. 2023 Jan 6;9:1063170. doi: 10.3389/fsurg.2022.1063170. eCollection 2022.

Unique anabolic action of stem cell gene therapy overexpressing PDGFB-DSS6 fusion protein in OVX osteoporosis mouse model.在去卵巢骨质疏松小鼠模型中，过表达血小板源性生长因子B-DSS6融合蛋白的干细胞基因治疗的独特合成代谢作用。

Bone Rep. 2019 Dec 11;12:100236. doi: 10.1016/j.bonr.2019.100236. eCollection 2020 Jun.

Changes in bone mineral density and bone metabolic indexes in ankylosing spondylitis mouse model complicated with osteoporosis.合并骨质疏松的强直性脊柱炎小鼠模型的骨密度及骨代谢指标变化

Exp Ther Med. 2018 Aug;16(2):811-815. doi: 10.3892/etm.2018.6220. Epub 2018 May 24.

Periodontal Biology: Stem Cells, Bmp2 Gene, Transcriptional Enhancers, and Use of Sclerostin Antibody and Pth for Treatment of Periodontal Disease and Bone Loss.牙周生物学：干细胞、Bmp2基因、转录增强子以及硬化蛋白抗体和甲状旁腺激素在牙周疾病和骨质流失治疗中的应用

Cell Stem Cells Regen Med. 2017;3(1). doi: 10.16966/2472-6990.113. Epub 2017 Jan 27.

Prevalence of and factors associated with adopting bone health promoting behaviours among people with osteoporosis in Taiwan: a cross-sectional study.台湾骨质疏松症患者中促进骨骼健康行为的患病率及相关因素：一项横断面研究。

BMJ Open. 2017 Sep 25;7(9):e015980. doi: 10.1136/bmjopen-2017-015980.

New anabolic therapies for osteoporosis.骨质疏松症的新合成代谢治疗方法。

Intern Emerg Med. 2017 Oct;12(7):915-921. doi: 10.1007/s11739-017-1719-4. Epub 2017 Aug 5.

Profile of romosozumab and its potential in the management of osteoporosis.罗莫单抗简介及其在骨质疏松症管理中的潜力。

Drug Des Devel Ther. 2017 Apr 13;11:1221-1231. doi: 10.2147/DDDT.S127568. eCollection 2017.

Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.台湾地区特立帕肽治疗持续性、依从性与骨折发生率之间的关联：基于全民健康保险研究数据库的分析

Osteoporos Int. 2016 Sep;27(9):2855-2865. doi: 10.1007/s00198-016-3611-x. Epub 2016 May 12.

Sclerostin Inhibition in the Management of Osteoporosis.硬化素抑制在骨质疏松症治疗中的应用

Calcif Tissue Int. 2016 Apr;98(4):370-80. doi: 10.1007/s00223-016-0126-6. Epub 2016 Mar 26.

本文引用的文献

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.一项关于抗硬化蛋白抗体布洛索单抗在绝经后低骨密度女性中的随机、双盲2期临床试验。

J Bone Miner Res. 2015 Feb;30(2):216-24. doi: 10.1002/jbmr.2351.

Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.骨硬化蛋白抗体增加骨形成和骨量的组织水平机制。

J Bone Miner Res. 2014 Jun;29(6):1424-30. doi: 10.1002/jbmr.2152.

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.绝经后骨质疏松症妇女使用地舒单抗和特立帕肽治疗 2 年（DATA 扩展研究）：一项随机对照试验。

J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.

Romosozumab in postmenopausal women with low bone mineral density.罗莫佐单抗治疗绝经后低骨密度妇女。

N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.特立帕肽和地舒单抗，单独或联合使用，治疗绝经后骨质疏松症女性：DATA 研究随机试验。

Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15.

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.骨疾病中骨硬化蛋白和 Dickkopf-1 作为治疗靶点。

Endocr Rev. 2012 Oct;33(5):747-83. doi: 10.1210/er.2011-1060. Epub 2012 Jun 20.

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.AMG 785，一种硬骨素单克隆抗体的单次剂量、安慰剂对照、随机研究。

J Bone Miner Res. 2011 Jan;26(1):19-26. doi: 10.1002/jbmr.173.

Sclerostin: current knowledge and future perspectives.骨硬化蛋白：当前的认识和未来展望。

Calcif Tissue Int. 2010 Aug;87(2):99-107. doi: 10.1007/s00223-010-9372-1. Epub 2010 May 15.

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.两剂硬骨素抗体可增加食蟹猴的骨形成、骨密度和骨强度。

J Bone Miner Res. 2010 May;25(5):948-59. doi: 10.1002/jbmr.14.

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.硬化蛋白抗体治疗可增加绝经后骨质疏松大鼠模型的骨形成、骨量和骨强度。

J Bone Miner Res. 2009 Apr;24(4):578-88. doi: 10.1359/jbmr.081206.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验